Verve Therapeutics Inc Stock

$6.01

4.60% day before yesterday

Nasdaq, Dec 27, 10:15 pm CET

ISIN

US92539P1012

Symbol

VERV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Verve Therapeutics Inc Stock price

$6.02

-25.90 81.14% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

-0.28 4.44%

ISIN

US92539P1012

Symbol

VERV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Key metrics

Market capitalization	$509.68m
Enterprise Value	$41.02m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	1.68
P/S ratio (TTM) P/S ratio	20.89
P/B ratio (TTM) P/B ratio	1.00
Revenue growth (TTM) Revenue growth	219.91%
Revenue (TTM) Revenue	$24.40m
EBIT (operating result TTM) EBIT	$-226.54m
Free Cash Flow (TTM) Free Cash Flow	$-162.06m
Cash position	$539.92m
EPS (TTM) EPS	$-2.46
P/E forward	negative
P/S forward	22.37
EV/Sales forward	1.80
Short interest	25.20%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Verve Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Verve Therapeutics Inc forecast:

9x Buy

82%

2x Hold

18%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Verve Therapeutics Inc forecast:

Buy

82%

Hold

18%

Analyst Estimates with Stock Price Targets

Financial data from Verve Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	24 24	220% 220% 100%
- Direct Costs	6.57 6.57	43% 43% 27%
Gross Profit	18 18	556% 556% 73%
- Selling and Administrative Expenses	42 42	60% 60% 171%
- Research and Development Expense	196 196	12% 12% 804%
EBITDA	-220 -220	7% 7% -902%
- Depreciation and Amortization	6.57 6.57	43% 43% 27%
EBIT (Operating Income) EBIT	-227 -227	4% 4% -928%
Net Profit	-197 -197	2% 2% -808%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Verve Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

29 days ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29, 2024, the company granted equity awards to one new employee, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to such new employee entering into employment with...

Neutral

GlobeNewsWire

●

about 2 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON , Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024, the company granted equity awards to six new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment wit...

Neutral

PRNewsWire

●

2 months ago

Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV

LOS ANGELES , Oct. 28, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of VERV during the cla...

More Verve Therapeutics Inc News

Company Profile

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, and Burt A. Adelman in 2018 and is headquartered in Cambridge, MA.

Head office	United States
CEO	Sekar Kathiresan
Employees	255
Founded	2018
Website	www.vervetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now